Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System

Overview

The objective of the study is to evaluate the safety and effectiveness of the Route 92 Medical Reperfusion System when used to aspirate emboli in acute ischemic stroke patients.

Full Title of Study: “A Prospective, Single-arm, Interventional Clinical Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical MonoPoint Reperfusion System for Aspiration Embolectomy in Acute Ischemic Stroke Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 22, 2021

Detailed Description

The objective of the study is to evaluate the safety and effectiveness of the Route 92 Medical Reperfusion System when used to aspirate emboli in acute ischemic stroke patients. The study design is an interventional, prospective, single-arm, open label clinical trial.

Interventions

  • Device: Thrombectomy
    • The Route 92 Medical Reperfusion System is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease within the internal carotid, middle cerebral, basilar and vertebral arteries.

Arms, Groups and Cohorts

  • Experimental: Thrombectomy
    • Aspiration of clot with large bore catheter in acute ischemic stroke patients

Clinical Trial Outcome Measures

Primary Measures

  • Effectiveness
    • Time Frame: Procedure
    • The primary effectiveness endpoint is arterial revascularization as measured by a modified Thrombolysis in Cerebrovascular Infarction (mTICI) score of 2b or greater at the end of angiography after all endovascular treatments.
  • Device-related peri-procedural complications
    • Time Frame: Procedure
    • dissection or perforation
  • Symptomatic Intracranial Cerebral Hemorrhage (SICH)
    • Time Frame: 24 hour
    • defined as type 2 parenchymal hemorrhage with a deterioration in National Institutes of Health Stroke Scale [NIHSS] score of >=4 points
  • Embolization to a previously uninvolved territory
    • Time Frame: Procedure
    • Embolization to a previously uninvolved territory

Secondary Measures

  • NIHSS score
    • Time Frame: 24 hours after treatment
    • The National Institutes of Health Stroke Scale (NIHSS) is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke
  • Modified Rankin Score
    • Time Frame: 90 days after treatment
    • The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or who have other causes of neurological disability
  • Procedure Time
    • Time Frame: Procedure
    • Total procedure time from insertion of Route 92 Reperfusion System to final angiogram
  • Procedure-Related SAEs
    • Time Frame: Procedure
    • Serious Adverse Events related to the interventional procedure

Participating in This Clinical Trial

Inclusion Criteria

1. The consent process has been completed with the subject, Legally Authorized Representative, or two physician best interest and consent is documented 2. Age >18 years 3. Clinical signs consistent with an acute ischemic stroke 4. Baseline National Institutes of Health Stroke Scale (NIHSS) score >= 6 5. Pre-stroke modified Rankin Score (mRS) <= 2 6. Acute occlusion of the M1 segment of the middle cerebral artery (MCA), internal carotid artery (ICA), vertebral or basilar arteries confirmed via computed tomography angiography (CTA) and/or magnetic resonance angiography (MRA) 7. The Investigator estimates that at least one delivery of the Route 92 Medical Reperfusion System can be completed within 24 hours of time last known well 8. In the opinion of the Investigator, reperfusion of the ischemic territory will result in clinical benefit 9. Angiographic confirmation of an occlusion of the M1 segment* of the middle cerebral artery, internal carotid artery, vertebral or basilar arteries with a modified Thrombolysis In Cerebral Infarction (mTICI) scale score of 0-1 Exclusion Criteria:

1. Known pregnancy or breast feeding 2. Known comorbidity that may complicate treatment or prevent improvement or follow-up 3. Known life expectancy < 12 months 4. Known history of severe allergy to contrast medium 5. Subject known to have suffered a stroke in the past 90 days 6. Subject participating in another study involving an investigational device or drug. 7. Known connective tissue disorder affecting the arteries (e.g. Marfan syndrome, fibromuscular dysplasia, Ehlers-Danlos syndrome) 8. Any known pre-existing hemorrhagic or coagulation deficiency 9. Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of recent/ fresh hemorrhage 10. Baseline CT or MRI showing intracranial tumor (except small meningioma) 11. Angiographic evidence of dissection in the extracranial or intracranial arteries 12. Angiographic evidence of carotid dissection 13. Angiographic evidence of multiple vascular occlusions (e.g., bilateral anterior circulation, anterior/posterior circulation). Note: tandem occlusions may be included at the discretion of the operating physician.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Route 92 Medical, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Stefan Brew, MBChB, MHB, Principal Investigator, Auckland City Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.